Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalberthome:othertreatments:chemotherapy [09.14.2022] (current) – external edit 127.0.0.1
Line 19: Line 19:
 There are variety of kinds of chemotherapy, but all chemotherapeutic regimens can cause depression of the immune system, often by paralyzing the bone marrow and leading to a decrease of white blood cells, red blood cells, and platelets. While some of the human cells which die are infected by intracellular pathogens, many are not. Chemotherapy's immunosuppressive effects are especially problematic when one considers that patients with cancer are already in a state of immunosuppression. In fact, according to the Marshall Pathogenesis, patients develop cancer because they are immunosuppressed. There are variety of kinds of chemotherapy, but all chemotherapeutic regimens can cause depression of the immune system, often by paralyzing the bone marrow and leading to a decrease of white blood cells, red blood cells, and platelets. While some of the human cells which die are infected by intracellular pathogens, many are not. Chemotherapy's immunosuppressive effects are especially problematic when one considers that patients with cancer are already in a state of immunosuppression. In fact, according to the Marshall Pathogenesis, patients develop cancer because they are immunosuppressed.
  
-When the body is immunosuppressed, there are a number of important genes that are not properly expressed including those transcribed by the Vitamin D Receptor (VDR). One such gene is tumor metastasis suppressor protein,(({{pubmed>long:16002434}})) a protein which acts to slow or prevent metastases (secondary tumors) from spreading in the body of an organism with cancer.(({{pubmed>long:2405170}}))+When the body is immunosuppressed, there are a number of important genes that are not properly expressed including those transcribed by the Vitamin D Receptor (VDR). One such gene is tumor metastasis suppressor protein,(({{pmid>long:16002434}})) a protein which acts to slow or prevent metastases (secondary tumors) from spreading in the body of an organism with cancer.(({{pmid>long:2405170}}))
  
-The additional immunosuppression caused by chemotherapy can cause symptoms over the long-term such as "chemo brain."(({{pubmed>long:16381547}}))+The additional immunosuppression caused by chemotherapy can cause symptoms over the long-term such as "chemo brain."(({{pmid>long:16381547}}))
  
 +==== Chemo brain ====
  
 +Brain fog (also known as "chemo brain") is a common side effect of chemotherapy. As demonstrated in a [[https://www.reuters.com/article/2011/11/14/us-cancer-breast-brain-idUSTRE7AD26V20111114|2011 study]], women with breast cancer, compared with healthy controls, had significantly reduced activation in several regions of the brain including the left middle dorsolateral prefrontal cortex, premotor cortex and left caudal lateral prefrontal cortex activation.(({{pmid>long:22084128}}))
  
-===== Methotrexate ===== 
  
-Methotrexate (MTX) is an antibiotic, which interferes with bacteria's ability to synthesize folate. It is used to treat diseases with rapid cell growth such as cancer and some autoimmune diseases. A superior alternative to MTX is the Marshall Protocol antibiotic, Bactrim DS: 
  
-<blockquote>MTX is an anti-folate – actually it is an anti-dihydrofolate reductase (anti-DHFR) – which inhibits one stage in the formation of DNA. Thus any bacteria dwelling within a body which has MTX in the bloodstream will find it more difficult to replicate, and hopefully the bacteria will gradually die off. Bactrim (Sulfa/trimeth) not only blocks DHFR (with trimethoprim) but also blocks P-ABA with Sulfonamide. Here is a diagram showing the Folate biochemistry in more detail. As you know, Bactrim is not a terribly effective antibiotic against intracellular pathogens, at least acting on its own. Neither is MTX especially effective acting on its own. 
  
-The interesting thing is that Folic Acid supplements are often given to ease the "side effects" of MTX. Folic Acid directly reduces the antibiotic action of both Trimethoprim and MTX. Sure, this may reduce pain from the immunopathology, but wouldn't it be more sensible to just lower the dose of MTX and reduce the risk of liver damage. 
  
-//**Trevor Marshall, PhD**// </blockquote> 
-==== Discontinuing methotrexate ==== 
  
-The antibiotic action of MTX is likely to increase the immunopathology associated with olmesartan (Benicartherapy, which is why patients should discontinue MTX before starting the Marshall Protocol.+===== Methotrexate ===== 
 + 
 +<mainarticle> [[home:othertreatments:antibacterials:methotrexate|Methotrexate]] </article> 
 + 
 +Methotrexate (MTXis an antibiotic, which interferes with bacteria's ability to synthesize folate. It is used to treat diseases with rapid cell growth such as cancer and some autoimmune diseases. A superior alternative to MTX is the Marshall Protocol antibiotic, Bactrim DS.
  
-It is not harmful to the body to discontinue MTX abruptly. This is in contrast to Prednisone, where abruptly stopping can cause a number of serious problems. Some doctors think there is a risk of rebound inflammation from stopping methotrexate abruptly. Taking a few weeks to wean from MTX, while probably not necessary, is the cautious approach to avoid the symptoms of rebound inflammation. 
  
 ===== Rituximab ===== ===== Rituximab =====
  
  
-In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed>long:22039471}})) This positive result may be due to the fact that Rituximab is a strong immunosuppressant. It may be telling to see a follow up of the patients who received the drug ten or even fifteen years from now.+In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pmid>long:22039471}})) This positive result may be due to the fact that Rituximab is a strong immunosuppressant. It may be telling to see a follow up of the patients who received the drug ten or even fifteen years from now.
  
 =====  Patient interviews  ===== =====  Patient interviews  =====
Line 58: Line 57:
 sarcoidosis, bladder cancer sarcoidosis, bladder cancer
  
-Read the [[http://bacteriality.com/2008/07/18/interview24/|interview]]+Read the [[https://bacteriality.com/2008/07/18/interview24/|interview]]
  
 <html></div></div></html> <html></div></div></html>
Line 90: Line 89:
  
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
-TECHEDIT+
  
  
   * Legacy content   * Legacy content
-    * http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=45587#p45587 s43 +    * https://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=45587#p45587 s43 
-    * http://www.marshallprotocol.com/view_topic.php?id=4285&forum_id=37&jump_to=91300#p91300 s132 +    * https://www.marshallprotocol.com/view_topic.php?id=4285&forum_id=37&jump_to=91300#p91300 s132 
-    * http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=28072#p28072 s31+    * https://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=28072#p28072 s31
     *      * 
  
Line 109: Line 109:
 3. SavageL.High-intensitychemotherapydoesnotimprovesurvivalinsmallcelllung cancer. J Natl Cancer Inst. 2008;100:519. 4. BearHD.Earlierchemotherapyforbreastcancer:perhapstoolatebutstilluseful. Ann Surg Oncol. 2003;10(4):334-335. 3. SavageL.High-intensitychemotherapydoesnotimprovesurvivalinsmallcelllung cancer. J Natl Cancer Inst. 2008;100:519. 4. BearHD.Earlierchemotherapyforbreastcancer:perhapstoolatebutstilluseful. Ann Surg Oncol. 2003;10(4):334-335.
  
-//**H.H. Weng**//(({{pubmed>long:18827215}}))+//**H.H. Weng**//(({{pmid>long:18827215}}))
  
 Some more interesting stuff here: Some more interesting stuff here:
-http://jama.ama-assn.org/cgi/content/full/300/13/1580+https://jama.ama-assn.org/cgi/content/full/300/13/1580
  
  In cancer research, system behavior has been monitored during cancer progression, demonstrating that cancer evolution is driven by multiple cycles of transition between genome system stability and instability.9-10 Chemotherapy, by and large, induces a relatively stable system to enter into a chaotic phase. This drastic treatment might be more harmful at the individual level than had been expected. Clearly, understanding the entire system response in the context of any specific treatment is key.  In cancer research, system behavior has been monitored during cancer progression, demonstrating that cancer evolution is driven by multiple cycles of transition between genome system stability and instability.9-10 Chemotherapy, by and large, induces a relatively stable system to enter into a chaotic phase. This drastic treatment might be more harmful at the individual level than had been expected. Clearly, understanding the entire system response in the context of any specific treatment is key.
Line 122: Line 122:
  
    
-<blockquote>Chemo: http://www.cancerdecisions.com/030506.html http://www.australianprescriber.com/magazine/29/1/2/3/</blockquote> +<blockquote>Chemo: https://www.cancerdecisions.com/030506.html https://www.australianprescriber.com/magazine/29/1/2/3/</blockquote> 
-===== References =====+===== References =====</nodisp> 
home/othertreatments/chemotherapy.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.